文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性呼吸窘迫综合征中高水平表达于髓系细胞样转录本-1的阳性微粒与不良结局相关,而糖蛋白1b+微粒无关

High Levels of Triggering Receptor Expressed in Myeloid Cells-Like Transcript-1 Positive, but Not Glycoprotein 1b+, Microparticles Are Associated With Poor Outcomes in Acute Respiratory Distress Syndrome.
PubMed 文献 · Crit Care Explor · 2024-06-27
一句话结论在ARDS患者中,TLT-1+血小板来源微粒高于中位数者死亡风险为较低者的3.7倍(p<0.001),而Gp1b+微粒与结局无关。

该回顾性队列研究利用ARDS Network临床试验(ARMA、KARMA、LARMA)中564例ARDS患者的血浆样本,用流式细胞术定量TLT-1、糖蛋白1b或αIIbβIIIa免疫阳性微粒,并与临床结局关联。结果未发现Gp1b+微粒与任何队列临床结局相关;αIIbβIIIa+和TLT-1+微粒按四分位分层与生存、无通气呼吸和血小板减少相关(χ2 p<0.001)。64例未能实现无辅助呼吸的患者中63例TLT+血小板来源微粒位于第75百分位。三个队列中TLT+微粒高于中位数者APACHE III评分更高、更易出现血小板减少,校正其他危险因素后死亡风险为较低者的3.7倍(p<0.001)。

要点

  • ARDS患者中TLT+微粒高于中位数者校正其他危险因素后死亡风险为低于中位数者的3.7倍(p<0.001)。
  • 64例未能实现无辅助呼吸的ARDS患者中,63例TLT+血小板来源微粒位于第75百分位。
  • Gp1b+微粒与任何队列的临床结局均无关联。
  • αIIbβIIIa+和TLT-1+微粒按四分位分层与生存、无通气呼吸及血小板减少相关(χ2 p<0.001)。
  • TLT+微粒高于中位数者APACHE III评分更高、更易出现血小板减少。

适用人群与场景

  • ARMA、KARMA、LARMA(研究01和03,低潮气量对比高潮气量、酮康唑治疗、利索茶碱治疗临床试验)ARDS Network临床试验中确诊ARDS的564例患者。

研究设计与关键结果

  • 研究类型为回顾性队列研究,样本量564例ARDS患者,数据来自ARMA、KARMA、LARMA(研究01和03,低潮气量对比高潮气量、酮康唑治疗、利索茶碱治疗临床试验)ARDS Network临床试验。
  • 用流式细胞术证实新鲜供者血浆中存在结合纤维蛋白原的TLT-1+血小板来源微粒(PMP)。
  • 回顾性定量ARDS患者血浆中TLT-1、糖蛋白1b或αIIbβIIIa免疫阳性微粒,并评估其与临床结局的关系。
  • 任何队列中均未发现Gp1b+微粒与临床结局的关联。
  • 按四分位分层,αIIbβIIIa+和TLT-1+微粒与生存、无通气呼吸和血小板减少相关(χ2 p<0.001)。
  • 64例未能实现无辅助呼吸的患者中,63例TLT+血小板来源微粒位于第75百分位。
  • 三个队列中,TLT+微粒计数高于中位数者APACHE III评分更高、更易出现血小板减少,校正其他危险因素后死亡风险为低于中位数者的3.7倍(p<0.001)。
  • 结论认为αIIbβIIIa+和TLT+微粒均与死亡率相关,但TLT-1+微粒与APACHE III评分、无辅助呼吸和多系统器官衰竭的相关性更强。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些发现值得进一步探索TLT-1+血小板来源微粒在ARDS或急性肺损伤进展中的机制作用。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To identify triggering receptor expressed in myeloid cells-like transcript-1 positive (TLT-1+) microparticles (MPs) and evaluate if their presence is associated with clinical outcomes and/or disease severity in acute respiratory distress syndrome (ARDS).

DESIGN: Retrospective cohort study.

SETTING: ARDS Network clinical trials.

PATIENTS: A total of 564 patients were diagnosed with ARDS.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Using flow cytometry, we demonstrated the presence of TLT-1+ platelet-derived microparticles (PMP) that bind fibrinogen in plasma samples from fresh donors. We retrospectively quantified TLT-1, glycoprotein (Gp) 1b, or αIIbβIIIa immunopositive microparticles in plasma samples from patients with ARDS enrolled in the ARMA, KARMA, and LARMA (Studies 01 and 03 lower versus higher tidal volume, ketoconazole treatment, and lisofylline treatment Clincial Trials) ARDS Network clinical trials and evaluated the relationship between these measures and clinical outcomes. No associations were found between Gp1b+ MPs and clinical outcomes for any of the cohorts. When stratified by quartile, associations were found for survival, ventilation-free breathing, and thrombocytopenia with αIIbβIIIa+ and TLT-1+ MPs (χ2p < 0.001). Notably, 63 of 64 patients in this study who failed to achieve unassisted breathing had TLT+ PMP in the 75th percentile. In all three cohorts, patients whose TLT+ MP counts were higher than the median had higher Acute Physiology and Chronic Health Evaluation III scores, were more likely to present with thrombocytopenia and were 3.7 times (p < 0.001) more likely to die than patients with lower TLT+ PMP after adjusting for other risk factors.

CONCLUSIONS: Although both αIIbβIIIa+ and TLT+ microparticles (αIIbβIIIa, TLT-1) were associated with mortality, TLT-1+ MPs demonstrated stronger correlations with Acute Physiology and Chronic Health Evaluation III scores, unassisted breathing, and multiple system organ failure. These findings warrant further exploration of the mechanistic role of TLT-1+ PMP in ARDS or acute lung injury progression.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Gibson AD, Bayrón-Marrero Z, Nieves-Lopez B, et al. High Levels of Triggering Receptor Expressed in Myeloid Cells-Like Transcript-1 Positive, but Not Glycoprotein 1b+, Microparticles Are Associated With Poor Outcomes in Acute Respiratory Distress Syndrome. Crit Care Explor. 2024. PMID: 38935146. doi:10.1097/CCE.0000000000001108

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。